Trial of personalised care after treatment-Prostate cancer: A randomised feasibility trial of a nurse-led psycho-educational intervention.


Journal

European journal of cancer care
ISSN: 1365-2354
Titre abrégé: Eur J Cancer Care (Engl)
Pays: England
ID NLM: 9301979

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 22 02 2018
accepted: 21 10 2018
pubmed: 28 11 2018
medline: 23 7 2019
entrez: 28 11 2018
Statut: ppublish

Résumé

The present parallel randomised control trial evaluated the feasibility of a nurse-led psycho-educational intervention aimed at improving the self-management of prostate cancer survivors. We identified 305 eligible patients from a district general hospital, diagnosed 9-48 months previously, who completed radical treatment, or were monitored clinically (ineligible for treatment). Ninety-five patients were recruited by blinded selection and randomised to Intervention (N = 48) and Control (N = 47) groups. Participant allocation was revealed to patients and researchers after recruitment was completed. For 36 weeks, participants received augmented usual care (Control) or augmented usual care and additional nurse support (Intervention) provided in two community hospitals and a university clinic, or by telephone. Data from 91 participants (Intervention, N = 45; Control, N = 46) were analysed. All feasibility metrics met predefined targets: recruitment rate (31.15%; 95% CI: 25.95%-36.35%), attrition rate (9.47%; 95% CI: 3.58%-15.36%) and outcome measures completion rates (77%-92%). Forty-five patients received the intervention, with no adverse events. The Extended Prostate Cancer Index Composite can inform the minimum sample size for a future effectiveness trial. The net intervention cost was £317 per patient. The results supported the feasibility and acceptability of the intervention, suggesting that it should be evaluated in a fully powered trial to assess its effectiveness and cost-effectiveness.

Identifiants

pubmed: 30478975
doi: 10.1111/ecc.12966
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Pagination

e12966

Subventions

Organisme : Macmillan Cancer Support
ID : 4237574

Informations de copyright

© 2018 John Wiley & Sons Ltd.

Auteurs

Marian Andrei Stanciu (MA)

North Wales Centre for Primary Care Research, Bangor University, Wrexham, UK.

Caroline Morris (C)

Betsi Cadwaladr University Health Board, Wrexham, UK.

Matt Makin (M)

Betsi Cadwaladr University Health Board, Wrexham, UK.

Eila Watson (E)

Department of Clinical Health Care, Oxford Brookes University, Oxford, UK.

Jenna Bulger (J)

North Wales Centre for Primary Care Research, Bangor University, Wrexham, UK.

Richard Evans (R)

North Wales Centre for Primary Care Research, Bangor University, Wrexham, UK.

Julia Hiscock (J)

North Wales Centre for Primary Care Research, Bangor University, Wrexham, UK.

Zoë Hoare (Z)

North Wales Organisation for Randomised Trials in Health, Bangor University, Bangor, UK.

Rhiannon Tudor Edwards (RT)

Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK.

Richard D Neal (RD)

Academic Unit of Primary Care, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.

Seow Tien Yeo (ST)

Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK.

Clare Wilkinson (C)

North Wales Centre for Primary Care Research, Bangor University, Wrexham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH